Zai Lab PEG

Mitä Zai Lab tekee? Zai Lab Ltd is a biopharmaceutical company headquartered in Shanghai, China. The company has 1,194 employees and completed its initial public offering on September 28, 2020. Zai Lab focuses on discovering, licensing, developing, and commercializing proprietary therapeutics for significant unmet medical needs in the Chinese market. Its primary therapeutic areas include oncology, autoimmune diseases, and infectious diseases. The company maintains a diverse pipeline of drug candidates spanning from early discovery stages to late-stage clinical development. Among its pipeline assets are Niraparib (ZL-2306), ZL-2103, and ZL-1101, though specific details about these compounds are not provided. Zai Lab operates within the health care sector, specifically in the biotechnology industry. The company's website is www.zailaboratory.com, and it is listed on the Hong Kong Stock Exchange under the ticker symbol 9688.HK. The ISIN for the company is KYG9887T1168. Zai Lab's business model centers on addressing critical healthcare gaps in China through innovative drug development, with a particular emphasis on locally relevant medical conditions. The company does not disclose additional details about its product pipeline beyond the mentioned compounds, and its operations are based in Shanghai, China. Zai Lab on yksi Eurpooliin suosituimmista yhtiöistä.